u-Sheng Chen, Ph.D.

—— Technical advisor of GENE TECH
EDUCATION：
Ph.D., Biochemistry, University of Miami, USA, 1977
M.S., Pharmacology, University of Miami, USA, 1974
B.S., Agricultural Chemistry, National Taiwan University, Taiwan, 1969
PROFESSIONAL EXPERIENCES：
- Distinguished Investigator and Director, Division of Biotechnology and?? Pharmaceutical Research, National Health Research Institutes, Taiwan (2002– present)
- Distinguished Senior Investigator, Merck & Co., Pennsylvania, USA (1995 - 2002)
- Director, Atherosclerosis Research, Merck & Co. , Pennsylvania, USA (1990 - 1995)
- Senior Research Fellow, Merck & Co., Pennsylvania, USA (1987 - 1990)
- Research Fellow, Merck & Co., Pennsylvania, USA (1983 - 1987)
- Senior Research Biochemist, Merck & Co., Pennsylvania, USA (1980 - 1983)
RESEARCH INTERESTS：
Dr. Chen specializes in the fields of drug discovery and development –He specialized in lipid and plasma lipoprotein metabolism, biochemistry and molecular biology. At Merck, he is involved in the development of lipid-lowWering agents (Mevacor and Zocor) and licensing of Zetia from Schering Plough Pharmaceutical Company.
RESEARCH ACTIVITIES & ACCOMPLISHMENTS：
Dr. Chen has devoted himself to drug discovery for more than twenty years, starting from 1977 as a postdoctoral fellow of Cardiovascular Research Institute in University of California, then employed by Merck & Co., Inc. He joined NHRI in Jan. 2002 as the director of the Division of Biotechnology and Pharmaceutical Research (DBPR) to establish and conduct research on novel therapies for treatment of locally prevalent and emerging diseases. DBPR has implemented modern drug discovery technologies, including biology, medicinal chemistry, high-throughput robotic screening, molecular modeling and virtual screening to enhance its drug discovery efforts for treatment of cancer, HCV, enterovirus, dengue, diabetes, and obesity.
For years, Dr. Chen enthusiastically participated in many drug-discovery related conferences nationally and internationally. For instance, he organized and co-chaired “Biotechnology 1999, Biotechnology in Taiwan: Opportunities & Challenges in the New Millennium” and “U.S./Taiwan partnering in Bio/Pharm-2001 and Beyond” in Newark, U.S.A.
In addition, many academic honors are given to Dr. Chen, such as N.I.H. fellowship, and other society memberships including Sigma Xi, American Heart Association (Fellow, Council on Arteriosclerosis), American Society for Biochemistry and Molecular Biology, and Society of Chinese Bioscientists in America (SCBA). He is also a Board member of the BioPharm Division of SCBA.